Duality S.A.

Equities

DUA

PLDLITY00010

End-of-day quote Warsaw S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
1.52 ^PLN	+2.01%		-0.98%	+2.70%

05-15	Duality S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-20	Duality S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Duality S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 15, 2024 at 06:20 pm

Duality S.A. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was PLN 0.992151 million compared to PLN 1.33 million a year ago. Net income was PLN 0.317129 million compared to PLN 0.108038 million a year ago.

Latest news about Duality S.A.

Duality S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
Duality S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
BioNTech to Present Clinical Data Updates on Cancer Vaccine Candidates	03-11	MT
Tod's CEO says he has no plans to sell 'family business'	02-23	RE
BioNTech, Duality Biologics Obtain FDA Fast Track Designation for Ovarian Cancer Therapy Candidate	01-31	MT
BioNTech's Cancer Therapy Candidate Obtains Fast-track Designation from US FDA	01-31	MT
BioNTech, Duality Biologics Initiate Phase 3 Trial of Breast Cancer Drug	01-22	MT
BioNTech Begins Late-stage Study for Metastatic Breast Cancer Therapy Candidate	01-22	MT
BioNTech challenges AstraZeneca with breast cancer precision drug trial	01-22	RE
BioNTech, Duality Biologics Get US FDA Breakthrough Therapy Designation for Uterine Cancer Drug Candidate	12-21	MT
Duality S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Australia's Albanese to highlight trade on China visit as ties warm	11-03	RE
Duality S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23	CI
Introducing Janus, the exotic 'two-faced' white dwarf star	21/07/23	RE
HBM Holdings, Beigene Sign License Deal for Antibody-Drug Conjugate Program; HBM Shares Soar 20%	14/07/23	MT
Duality S.A. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
BioNTech, DualityBio Sign Strategic Partnership to Develop ADC Therapeutics to Treat Solid Tumors	03/04/23	MT
BioNTech Partners With DualityBio to Develop Cancer Treatments	03/04/23	MT
BioNTech, Duality Biologics Enter Licensing Agreement for Cancer Treatments	03/04/23	DJ
Credit Suisse on Hydro One: "All About Ontario with the Duality of Delivering Decarbonization and Defensive Growth"	31/03/23	MT
Swiss neutrality on the line as arms-for-Ukraine debate heats up	07/02/23	RE
Swiss neutrality on the line as arms-for-Ukraine debate heats up	06/02/23	RE
Analysis-Swiss neutrality on the line as arms-for-Ukraine debate heats up	06/02/23	RE
Historic UK satellite launch may spur military appetite	08/01/23	RE
Duality S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	14/11/22	CI

Chart Duality S.A.

Duration

Period

More charts

Company Profile

Sector

More about the company

Income Statement Evolution

More financial data